Medable, the leading technology providerfor modern clinical trials, today announced that Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, January 10,2024, at 7:30 AM Pacific Time (10:30 AM Eastern Time).



Medable, a Software as a Service (SaaS) cloud platform, is revolutionizing clinical drug development.  Our innovative AI-driven technology is transforming clinical trial evidence data collection, analysis, and application, resulting in increased speed and efficiency to bring life-saving therapies to patients faster.  We are accelerating the generation of critical evidence by digitizing and connecting with patients at consumer scale. The flexibility of our technology has powered300+ clinical trials, across 70+ countries, in 115+ languages, with over 1M patients having utilized our platform, ensuring broader, more diverse patient engagement.  Medable is trusted by 14 of the top 20 pharmaceutical companies and 9 of the top 10 CROs. To date, we have secured $500M+ in funding from top-tier investors, including Blackstone, Sapphire, PPD/ThermoFisher, and GSR Ventures.